CO2024012879A2 - Composición sólida que comprende antagonistas del receptor de bradicinina b2 solubilizados - Google Patents
Composición sólida que comprende antagonistas del receptor de bradicinina b2 solubilizadosInfo
- Publication number
- CO2024012879A2 CO2024012879A2 CONC2024/0012879A CO2024012879A CO2024012879A2 CO 2024012879 A2 CO2024012879 A2 CO 2024012879A2 CO 2024012879 A CO2024012879 A CO 2024012879A CO 2024012879 A2 CO2024012879 A2 CO 2024012879A2
- Authority
- CO
- Colombia
- Prior art keywords
- bradykinin
- methyl
- solubilized
- solid dispersions
- receptor antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22164462 | 2022-03-25 | ||
| PCT/EP2023/057791 WO2023180575A1 (en) | 2022-03-25 | 2023-03-27 | Solid composition comprising solubilised bradykinin b2-receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024012879A2 true CO2024012879A2 (es) | 2024-10-31 |
Family
ID=80952146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0012879A CO2024012879A2 (es) | 2022-03-25 | 2024-09-24 | Composición sólida que comprende antagonistas del receptor de bradicinina b2 solubilizados |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20250228781A1 (enExample) |
| EP (1) | EP4499038B1 (enExample) |
| JP (1) | JP2025512818A (enExample) |
| KR (1) | KR20240161689A (enExample) |
| CN (1) | CN119136785A (enExample) |
| AU (1) | AU2023241243A1 (enExample) |
| CA (1) | CA3250835A1 (enExample) |
| CO (1) | CO2024012879A2 (enExample) |
| ES (1) | ES3062067T3 (enExample) |
| HR (1) | HRP20260166T1 (enExample) |
| IL (1) | IL315699A (enExample) |
| MA (1) | MA69209B1 (enExample) |
| MX (1) | MX2024011703A (enExample) |
| PL (1) | PL4499038T3 (enExample) |
| WO (1) | WO2023180575A1 (enExample) |
| ZA (1) | ZA202408058B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102824038B1 (ko) | 2025-01-20 | 2025-06-23 | 송재혁 | 차량 종합 검사 시스템 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1168667A (zh) | 1994-10-27 | 1997-12-24 | 藤沢药品工业株式会社 | 用作缓激肽拮抗剂的吡啶并嘧啶酮，喹啉和稠合的n-杂环化合物 |
| FR2737892B1 (fr) | 1995-08-17 | 1997-10-24 | Fournier Ind & Sante | Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique |
| GB9602029D0 (en) | 1996-02-01 | 1996-04-03 | Fujisawa Pharmaceutical Co | New heterocyclic compounds |
| DE19609827A1 (de) | 1996-03-13 | 1997-09-18 | Hoechst Ag | Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten |
| DE19610784A1 (de) | 1996-03-19 | 1997-09-25 | Hoechst Ag | Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung |
| AUPN952696A0 (en) | 1996-04-29 | 1996-05-23 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| DE19712960A1 (de) | 1997-03-27 | 1998-10-01 | Hoechst Ag | Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten |
| EP1085895A1 (en) | 1998-06-08 | 2001-03-28 | Advanced Medicine, Inc. | Bradykinin antagonists |
| EP1123288A1 (en) | 1998-10-21 | 2001-08-16 | Fujisawa Pharmaceutical Co., Ltd. | Vitreous form of known bradykinin antagonist |
| FR2790260B1 (fr) | 1999-02-26 | 2001-05-04 | Fournier Ind & Sante | Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique |
| CA2364178C (en) | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| JP2005525398A (ja) | 2002-04-10 | 2005-08-25 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | ブラジキニン受容体モジュレーターとして有用な新規なヘテロアリールアルキルアミド誘導体 |
| ITMI20021247A1 (it) | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
| TWI407960B (zh) | 2007-03-23 | 2013-09-11 | Jerini Ag | 小分子緩激肽ｂ２受體調節劑 |
| AR073304A1 (es) | 2008-09-22 | 2010-10-28 | Jerini Ag | Moduladores del receptor de bradiquinina b2 de molecula pequena |
| KR20150127718A (ko) | 2013-03-14 | 2015-11-17 | 샤이어 휴먼 지네틱 테라피즈 인크. | Ｂ2-브라디키닌 수용체 매개 혈관부종의 치료 방법 |
| SMT202200154T1 (it) | 2017-11-24 | 2022-05-12 | Pharvaris Netherlands B V | Nuovi antagonisti del recettore della bradichinina b2 |
| AR118983A1 (es) * | 2019-05-23 | 2021-11-17 | Pharvaris Gmbh | Antagonistas cíclicos del receptor b2 de bradiquinina |
| CA3198246A1 (en) * | 2020-11-12 | 2022-05-19 | Pharvaris Gmbh | Prophylaxis and treatment of angioedema |
-
2023
- 2023-03-27 HR HRP20260166TT patent/HRP20260166T1/hr unknown
- 2023-03-27 AU AU2023241243A patent/AU2023241243A1/en active Pending
- 2023-03-27 CA CA3250835A patent/CA3250835A1/en active Pending
- 2023-03-27 PL PL23715487.7T patent/PL4499038T3/pl unknown
- 2023-03-27 US US18/850,679 patent/US20250228781A1/en active Pending
- 2023-03-27 EP EP23715487.7A patent/EP4499038B1/en active Active
- 2023-03-27 WO PCT/EP2023/057791 patent/WO2023180575A1/en not_active Ceased
- 2023-03-27 ES ES23715487T patent/ES3062067T3/es active Active
- 2023-03-27 IL IL315699A patent/IL315699A/en unknown
- 2023-03-27 KR KR1020247035351A patent/KR20240161689A/ko active Pending
- 2023-03-27 JP JP2024556786A patent/JP2025512818A/ja active Pending
- 2023-03-27 MA MA69209A patent/MA69209B1/fr unknown
- 2023-03-27 CN CN202380037794.6A patent/CN119136785A/zh active Pending
-
2024
- 2024-09-24 CO CONC2024/0012879A patent/CO2024012879A2/es unknown
- 2024-09-24 MX MX2024011703A patent/MX2024011703A/es unknown
- 2024-10-24 ZA ZA2024/08058A patent/ZA202408058B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4499038A1 (en) | 2025-02-05 |
| PL4499038T3 (pl) | 2026-04-27 |
| JP2025512818A (ja) | 2025-04-22 |
| IL315699A (en) | 2024-11-01 |
| EP4499038B1 (en) | 2025-12-03 |
| CN119136785A (zh) | 2024-12-13 |
| MX2024011703A (es) | 2024-11-08 |
| AU2023241243A1 (en) | 2024-11-07 |
| CA3250835A1 (en) | 2023-09-28 |
| KR20240161689A (ko) | 2024-11-12 |
| ZA202408058B (en) | 2026-01-28 |
| EP4499038C0 (en) | 2025-12-03 |
| HRP20260166T1 (hr) | 2026-03-27 |
| WO2023180575A1 (en) | 2023-09-28 |
| US20250228781A1 (en) | 2025-07-17 |
| MA69209B1 (fr) | 2026-03-31 |
| ES3062067T3 (en) | 2026-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022015622A (es) | Compuestos de dihidroquinolin sulfonamida de ciclopropilo. | |
| MX2025010506A (es) | Compuestos de dihidroquinolinsulfonamida de ciclobutilo | |
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| MX2022015857A (es) | Compuestos de dihidroquinolin sulfonamida de heteroalquilo. | |
| PE20060075A1 (es) | Composiciones farmaceuticas de alisciren | |
| CA2883751A1 (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
| EA201171109A1 (ru) | Новая композиция замедленного высвобождения соединений, выбранных из класса миорелаксантов центрального действия | |
| PH12022551359A1 (en) | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases | |
| MY130803A (en) | New quinuclidine amide derivatives | |
| SI2989100T1 (en) | NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6 | |
| JO3754B1 (ar) | أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون | |
| JP2007533686A5 (enExample) | ||
| AR040248A1 (es) | Farmaco para el tratamiento de la vejiga hiperactiva | |
| SI1735278T1 (sl) | Agenti histamin h receptorja priprava in terapevtska uporaba | |
| NO20080670L (no) | Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister | |
| AR069349A1 (es) | Uso de antagonistas del receptor trpv1 para el tratamiento del ojo y del dolor ocular | |
| WO2018005519A3 (en) | Cancer treatment combinations | |
| EA200870469A1 (ru) | Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение | |
| BRPI0912112B8 (pt) | composição farmacêutica compreendendo composto tendo atividade antagonística em receptor de adenosina a2a útil em suprimir tolerância analgésica | |
| JP2014237716A (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| TW201536295A (zh) | σ配體在與間質性膀胱炎／膀胱疼痛綜合徵（ＩＣ／ＢＰＳ）相關的疼痛的預防和治療中的應用 | |
| MX2024011703A (es) | Composicion solida que comprende antagonistas del receptor de bradicinina b2 solubilizados | |
| RU2011129830A (ru) | Производные 1-амино-алкилциклогексана для лечения заболеваний, опосредованных тучными клетками | |
| UY38707A (es) | Nuevos antagonistas cíclicos del receptor b2 de bradiquinina | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. |